Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.

"Financial/nonfinancial disclosures: The authors have reported to CHEST the following: R. H. C. reports grants from IDBiologics and 10.13039/100007723Takeda Vaccines, grants and other from 10.13039/100004325AstraZeneca, outside the submitted work; and has patents for COVID-19 human monoclonal antibodies (multiple) with licenses to AstraZeneca, IDBiologics, and Leinco and royalties paid to the US government. J. D. Casey reports grants from the National Institute of Health (NIH) outside the submitted work. J. D. Chappell reports grants from the 10.13039/100000002NIH and grants from the Dolly Parton COVID-19 Research Fund during the conduct of the study. J. E. C. reports serving as a consultant for Luna Innovations, 10.13039/100004334Merck, and 10.13039/100004330GlaxoSmithKline, and as a member of the Scientific Advisory Board of Meissa Vaccines and being the founder of IDBiologics; the laboratory of J. E. C. received sponsored research agreements from 10.13039/100004325AstraZeneca, 10.13039/100007723Takeda, and IDBiologics during the conduct of the study. 10.13039/100006537Vanderbilt University has applied for patents for some of the antibodies in this paper, for which J. E. C. is an inventor. W. E. A. reports grants from NCATS, during the conduct of the study, and grants from Biomedical Advanced Research and Development Authority (10.13039/100012399BARDA) outside the submitted work. P. G. reports that he is a co-inventor with Vanderbilt University on patents for SARS-CoV-2 human monoclonal antibodies (multiple) with licenses to AstraZeneca, IDBiologics, and Leinco and the US Government has certain rights to these antibodies. M. R. D. reports grants from the NIH and the Dolly Parton COVID-19 Research Fund during the conduct of this study. A. A. G. reports grants from the NIH, Department of Defense, the Centers for Disease Control and Prevention, and AbbVie, and grants from Faron Pharmaceuticals outside the submitted work. D. J. H. reports grants and personal fees from Cytovale, personal fees from Beckman-Coulter, and grants and personal fees from Opticyte outside the submitted work. C. J. L. reports grants from the NIH, Department of Defense, and the Centers for Disease Control and Prevention outside the submitted work; research contracts from bioMérieux, AbbVie, Entegrion, and Endpoint Health outside the submitted work; stock options in Bioscape Digital outside the submitted work; and patents (not licensed) for risk stratification in sepsis and septic shock issued to Cincinnati Children’s Hospital Medical Center outside the submitted work. T. W. R. reports receiving grant funding from the NIH for conducting this study and personal fees from Cumberland Pharmaceuticals, Inc; personal fees from Sanofi, Inc; and personal fees from Cytovale, Inc outside the submitted work. W. H. S. reports receiving grant funding from the NIH for conducting this study. L. J. S. reports grants from the NIH and grants from Dolly Parton COVID-19 Research Fund during the conduct of the study. None declared (A. P. W., T. G. S., H. S., J. M., C. B. T., V. D. C., H. R. O., N. I. S., C. H.; L. C., N. J. J., S. J. J., M. J. M., E. S. H., S. R. P., M. L.-V., M. d. W., D. H., C. S. C., C. M., C. S., A. E. J., J. S. R., S. M., T. S. I., X. Q., S. J. S., A. S., R. D. F., E. J. B., R. E. S.; I. T., S. M. Y., A. J. B.-H., L. W., J. M. P., J. P. R., G. R. B.)."

"Funding/support: Primary funding for this work was provided by 10.13039/100006108NCATS [3UL1TR002243-04S3]. Funding for pilot work was provided by the Dolly Parton COVID-19 Research Fund. Funding for Research Electronic Data Capture, trial innovation work, and the other data tools was provided by 10.13039/100006108NCATS [UL1TR002243]."

"Clinical Trial Registration ClinicalTrials.gov; No.: NCT04362176; URL: www.clinicaltrials.gov"